Target intelligence / Profile preview

Inactive tyrosine-protein phosphatase STYX (STYX)

Target
STYX
Molecular classification
Pseudophosphatase, Dual-specificity phosphatase (inactive variant), Protein tyrosine phosphatase (inactive form), Modular domain protein
01

Overview

Inactive tyrosine-protein phosphatase STYX (STYX) is a catalytically inactive member of the dual-specificity phosphatase family structurally similar to protein tyrosine phosphatases but lacking a critical active-site cysteine, rendering it enzymatically inactive[1][2][4]. Instead of dephosphorylation, STYX functions mainly by binding to phosphorylated proteins—serving as a nuclear anchor for ERK1/2 and regulating the duration and localization of ERK signaling[1]. This role modulates processes such as Golgi polarization, cell migration, and differentiation, with implications for the invasive and metastatic potential of cancer cells[1][2]. In various cell types, including cancer cells, STYX is involved in stress response modulation by inhibiting the assembly of stress granules through protein–protein interactions rather than direct enzymatic action[3]. STYX is upregulated in several cancers and acts as a potential oncogene, indicating promise as a diagnostic or prognostic biomarker and a candidate therapeutic target[2].

Other names
Serine/threonine/tyrosine-interacting proteinphosphoserine/threonine/tyrosine interaction proteinprotein tyrosine phosphatase-like proteinMK-STYXpseudophosphatase STYX
02

Biological functions

Regulation of ERK1/2 signalingModulation of cell migration and polarityRegulation of Golgi apparatus morphology and polarizationModulation of cell-fate decisions (e.g., differentiation)Regulation of stress granule assemblyModulation of protein-protein interactions in phosphorylation cascades
03

Disease associations

Cancer (oncogene in certain cancers, e.g., gastric cancer)Potential involvement in neurodegenerative diseases (via stress granule regulation or differentiation)Other (influences cell motility relevant for metastasis)
04

Safety considerations

None directly established; risk may relate to its modulation of central cell proliferation, differentiation, and migration pathways (e.g., potential for oncogenic transformation if dysregulated)
05

Biomarkers

STYX expression (potential biomarker for cancer prognosis, especially gastric cancer)

Beyond the preview

Go deeper on Inactive tyrosine-protein phosphatase STYX (STYX).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inactive tyrosine-protein phosphatase STYX (STYX).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call